Switch theme
Sign up to access all valuation multiples
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
1996
61
Last FY Revenue n/a
LTM EBITDA -$124M
-$58.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Acumen Pharmaceuticals has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$124M.
In the most recent fiscal year, Acumen Pharmaceuticals achieved revenue of n/a and an EBITDA of -$98.1M.
Acumen Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Acumen Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$124M | XXX | -$98.1M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$122M | XXX | -$114M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$115M | XXX | -$102M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Acumen Pharmaceuticals's stock price is $1.
Acumen Pharmaceuticals has current market cap of $61.8M, and EV of -$58.4M.
See Acumen Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$58.4M | $61.8M | XXX | XXX | XXX | XXX | $-1.86 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Acumen Pharmaceuticals has market cap of $61.8M and EV of -$58.4M.
Acumen Pharmaceuticals's trades at n/a EV/Revenue multiple, and 0.6x EV/EBITDA.
Equity research analysts estimate Acumen Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Acumen Pharmaceuticals has a P/E ratio of -0.5x.
See valuation multiples for Acumen Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $61.8M | XXX | $61.8M | XXX | XXX | XXX |
| EV (current) | -$58.4M | XXX | -$58.4M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | 0.5x | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBIT | 0.5x | XXX | 0.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.5x | XXX | -0.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAcumen Pharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.9M for the same period.
Acumen Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Acumen Pharmaceuticals's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Acumen Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | 71% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Acumen Pharmaceuticals acquired XXX companies to date.
Last acquisition by Acumen Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Acumen Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Acumen Pharmaceuticals founded? | Acumen Pharmaceuticals was founded in 1996. |
| Where is Acumen Pharmaceuticals headquartered? | Acumen Pharmaceuticals is headquartered in United States of America. |
| How many employees does Acumen Pharmaceuticals have? | As of today, Acumen Pharmaceuticals has 61 employees. |
| Who is the CEO of Acumen Pharmaceuticals? | Acumen Pharmaceuticals's CEO is Mr. Daniel O'Connell. |
| Is Acumen Pharmaceuticals publicy listed? | Yes, Acumen Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Acumen Pharmaceuticals? | Acumen Pharmaceuticals trades under ABOS ticker. |
| When did Acumen Pharmaceuticals go public? | Acumen Pharmaceuticals went public in 2021. |
| Who are competitors of Acumen Pharmaceuticals? | Similar companies to Acumen Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Acumen Pharmaceuticals? | Acumen Pharmaceuticals's current market cap is $61.8M |
| Is Acumen Pharmaceuticals profitable? | Yes, Acumen Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Acumen Pharmaceuticals? | Acumen Pharmaceuticals's last 12 months EBITDA is -$124M. |
| What is the current EV/EBITDA multiple of Acumen Pharmaceuticals? | Current EBITDA multiple of Acumen Pharmaceuticals is 0.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
